PGGM Investments Acquires 779 Shares of Zoetis Inc. (NYSE:ZTS)

PGGM Investments increased its holdings in Zoetis Inc. (NYSE:ZTS) by 2.7% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 29,252 shares of the company’s stock after purchasing an additional 779 shares during the quarter. PGGM Investments’ holdings in Zoetis were worth $4,950,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ZTS. Hohimer Wealth Management LLC grew its holdings in shares of Zoetis by 1.2% during the fourth quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock valued at $866,000 after buying an additional 52 shares during the last quarter. Forum Financial Management LP grew its holdings in shares of Zoetis by 0.8% during the fourth quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock valued at $1,458,000 after buying an additional 56 shares during the last quarter. Angeles Wealth Management LLC grew its holdings in shares of Zoetis by 3.5% during the fourth quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock valued at $324,000 after buying an additional 56 shares during the last quarter. Prossimo Advisors LLC lifted its position in Zoetis by 1.7% during the fourth quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock valued at $690,000 after purchasing an additional 57 shares during the period. Finally, River Street Advisors LLC lifted its position in Zoetis by 3.4% during the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock valued at $347,000 after purchasing an additional 58 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS traded down $1.83 during mid-day trading on Friday, hitting $180.59. 2,699,619 shares of the company were exchanged, compared to its average volume of 1,898,130. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The company has a 50 day moving average of $175.44 and a 200-day moving average of $175.72. The stock has a market cap of $82.40 billion, a price-to-earnings ratio of 34.80, a price-to-earnings-growth ratio of 2.83 and a beta of 0.86.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same quarter in the prior year, the firm earned $1.31 EPS. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. Analysts expect that Zoetis Inc. will post 5.76 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, July 18th. This represents a $1.73 annualized dividend and a dividend yield of 0.96%. Zoetis’s dividend payout ratio (DPR) is presently 33.14%.

Analyst Ratings Changes

ZTS has been the subject of a number of research reports. Piper Sandler restated an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. HSBC decreased their target price on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Stifel Nicolaus decreased their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. BTIG Research initiated coverage on shares of Zoetis in a research report on Thursday, July 25th. They set a “buy” rating and a $220.00 target price for the company. Finally, Barclays decreased their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $212.67.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.